Burton Anya, Tataru Daniela, Driver Robert J, Bird Thomas G, Huws Dyfed, Wallace David, Cross Timothy J S, Rowe Ian A, Alexander Graeme, Marshall Aileen
HCC-UK/British Association for the Study of the Liver (BASL), Lichfield, UK.
National Cancer Registration and Analysis Service, National Disease Registration Service, Public Health England, London, UK.
JHEP Rep. 2021 Jan 19;3(2):100232. doi: 10.1016/j.jhepr.2021.100232. eCollection 2021 Apr.
BACKGROUND & AIMS: The incidence of primary liver cancer (PLC) is increasing in Western Europe. To understand trends over time and the current burden in the UK, a detailed analysis of the epidemiology of PLC and its subtypes was conducted.
Data on PLCs diagnosed during 1997-2017 were obtained from population-based, nationwide registries in the UK. European age-standardised incidence (ASR) and incidence-based mortality rates (ASMR) per 100,000 person-years were calculated overall and by sex and UK-nation. Annual percentage change in rates was estimated using Joinpoint regression. One-, 2-, and 5-year age-standardised net survival was estimated.
A total of 82,024 PLCs were diagnosed. Both hepatocellular carcinoma (HCC) incidence and mortality rates trebled (ASR 1.8-5.5 per 100,000, ASMR 1.3-4.0). The rate of increase appeared to plateau around 2014/2015. Scottish men consistently had the highest HCC incidence rates. PLC survival increased, driven by a substantial increase in the proportion that are HCC (as prognosis is better than other PLCs) and in HCC survival (change in 1-year survival 24-47%). Intrahepatic cholangiocarcinoma was the most common PLC in women and 1-year survival improved from 22.6% to 30.5%.
PLC incidence has been increasing rapidly but, as most risk factors are modifiable, it is largely a preventable cancer. This rate of increase has slowed in recent years, possibly attributable to effective treatment for hepatitis C. As other risk factors such as obesity and diabetes remain prevalent in the UK, it is unlikely the considerable burden of this disease will abate. While improvements in survival have been made, over half of patients are not alive after 1 year, therefore further progress in prevention, early detection, and treatment innovation are needed.
Many more people are getting liver cancer, particularly the subtype hepatocellular carcinoma, than 20 years ago. Men in Scotland are most likely to get liver cancer and to die from it. Survival after liver cancer diagnosis is getting longer but still less than half are alive after 1 year.
原发性肝癌(PLC)在西欧的发病率正在上升。为了解英国随时间推移的发病趋势及当前负担,我们对PLC及其亚型的流行病学进行了详细分析。
从英国基于人群的全国性登记处获取1997 - 2017年期间诊断的PLC数据。计算总体以及按性别和英国地区划分的每10万人年的欧洲年龄标准化发病率(ASR)和基于发病率的死亡率(ASMR)。使用Joinpoint回归估计发病率的年度百分比变化。估计1年、2年和5年的年龄标准化净生存率。
共诊断出82,024例PLC。肝细胞癌(HCC)的发病率和死亡率均增加了两倍(ASR从每10万人1.8例增至5.5例,ASMR从每10万人1.3例增至4.0例)。发病率的上升速度在2014/2015年左右似乎趋于平稳。苏格兰男性的HCC发病率一直最高。PLC的生存率有所提高,这是由于HCC所占比例大幅增加(因为其预后优于其他PLC)以及HCC生存率提高(1年生存率从24%提高到47%)所致。肝内胆管癌是女性中最常见的PLC亚型,其1年生存率从22.6%提高到30.5%。
PLC发病率一直在迅速上升,但由于大多数风险因素是可改变的,它在很大程度上是一种可预防的癌症。近年来发病率上升速度有所放缓,这可能归因于丙型肝炎的有效治疗。由于肥胖和糖尿病等其他风险因素在英国仍然普遍存在,这种疾病的沉重负担不太可能减轻。虽然生存率有所提高,但超过一半的患者在1年后无法存活,因此在预防、早期检测和治疗创新方面还需要进一步进展。
与20年前相比,患肝癌尤其是肝细胞癌亚型的人数更多。苏格兰男性最容易患肝癌并死于肝癌。肝癌诊断后的生存率正在提高,但1年后仍存活的患者仍不到一半。